Richard Eisenstadt
2015 - Neos Therapeutics
In 2015, Richard Eisenstadt earned a total compensation of $1.3M as Chief Financial Officer at Neos Therapeutics, a 197% increase compared to previous year.
Compensation breakdown
| Bonus | $5,520 |
|---|---|
| Non-Equity Incentive Plan | $66,241 |
| Option Awards | $854,524 |
| Salary | $315,030 |
| Other | $11,870 |
| Total | $1,253,185 |
Eisenstadt received $854.5K in option awards, accounting for 68% of the total pay in 2015.
Eisenstadt also received $5.5K in bonus, $66.2K in non-equity incentive plan, $315K in salary and $11.9K in other compensation.
Rankings
In 2015, Richard Eisenstadt's compensation ranked 6,844th out of 13,638 executives tracked by ExecPay. In other words, Eisenstadt earned more than 49.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,844 out of 13,638 | 50th |
Division Manufacturing | 2,580 out of 5,190 | 50th |
Major group Chemicals And Allied Products | 927 out of 1,854 | 50th |
Industry group Drugs | 746 out of 1,528 | 51st |
Industry Pharmaceutical Preparations | 581 out of 1,182 | 51st |
Source: SEC filing on April 28, 2017.
Eisenstadt's colleagues
We found two more compensation records of executives who worked with Richard Eisenstadt at Neos Therapeutics in 2015.
News
PharmAthene CEO Vipin Garg's 2022 pay rises 9% to $2.9M
August 16, 2023
PharmAthene CEO Vipin Garg's 2021 pay jumps 83% to $2.6M
August 16, 2022
AYTU BIOPHARMA CEO Joshua Disbrow's 2021 pay jumps 291% to $6.2M
April 7, 2022
Neos Therapeutics CEO Gerald McLaughlin's 2019 pay falls 56% to $1.4M
April 21, 2020
Neos Therapeutics CEO Gerald McLaughlin receives $3.2M in 2018
April 24, 2019